CardioExchange Archive

May 13th, 2014

The Effect of Incarceration on the Epidemiology of Heart Disease

Emily Wang, MD, MAS

Emily Wang discusses how studies of health outcomes are compromised when subjects, particularly black men, are incarcerated and can no longer be followed.

---

February 27th, 2014

Poor Medical Research: What Has Changed in 20 Years?

Harlan M. Krumholz, MD, SM

A recent blog and a 20-year-old editorial has Harlan Krumholz wondering: Why there is so much poor medical research?

---

December 20th, 2013

Researching the Obvious: It Stinks to Have Cancer

Debra Lynne Sherman, BA

Editor’s note: Debra Sherman is an outstanding, exceptionally perceptive health reporter who asked me recently why it is that so many medical research findings seem so unimportant and obvious. She is facing a critical illness and needs research that is useful. Those of us who do research should be asking ourselves if there is real value in […]

---

August 20th, 2013

A Pathway to Preventing Research Fraud

Harlan M. Krumholz, MD, SM

Is the road to fraud-free research paved with publicly accessible raw data?

---

June 10th, 2013

Research During Fellowship: Perspectives from the Protégé and the Mentor

Stephen Archer, MD and John Ryan, MD

In the first part of this post, CardioExchange’s John Ryan writes about the research he performed during his cardiology fellowship under the mentorship of Stephen Archer. In the second part, originally delivered at the Resident Research Day at Queen’s University, at which he is Professor and Head of the Department of Medicine, Archer gives his “elevator […]

---

April 11th, 2013

Journals, Journals, Everywhere

Tariq Ahmad, MD, MPH

Does creating more subspecialty journals contribute to the creation of too much information, about small aspects of the field, such that specialists move closer to “knowing everything about nothing”?

---

August 13th, 2012

Selections from Richard Lehman’s Literature Review: August 13th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include using existing data for new research; normal weight, diabetes, and non-CVD death; cholesterol levels in U.S. kids; statins and diabetes; HDL-C and MI protection; statin treatment; hypertension treatment; clopidogrel and PPIs; and an analysis behind the “innovation crisis” of the pharmaceutical industry.

---